At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 241 enrolled
Drug / intervention
OCS-01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery
In Brief
A Phase 3 clinical trial evaluating OCS-01 and Vehicle for Inflammation Eye Pain and Postoperative Cataract. Completed, enrolled 241 participants across 25 sites.
Detailed Summary
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation Eye Pain, Postoperative Cataract
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartJun 2022
Primary CompletionJun 2023
Study CompletionJul 2023
TodayJul 2026
First PostedDec 7, 2021
Enrollment StartJun 24, 2022
Primary CompletionJun 22, 2023
Study CompletionJul 3, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.6 years ago
Interventions
OCS-01drug
Dexamethasone ophthalmic suspension, 1.5%
Vehicledrug
Vehicle